Duration And Association With Protection Of NANP-Repeat Specific And C-Terminus-Specific Anti-Circumsporozoite Protein Igg Responses Following RTS,S/AS01E Vaccination: An Observational Ancillary Immunological Study Of A Phase 3 Clinical Trial
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
The Lancet Infectious Diseases
Abstract
Background The RTS,S/AS01E
malaria vaccine provides partial protection against Plasmodium falciparum, largely
mediated by antibodies targeting the circumsporozoite protein. Correlates of protection remain incompletely defined
and have focused mainly on peak IgG responses to the immunodominant NANP-repeats, with less known about
antibody durability or responses to the C-terminus of circumsporozoite protein.
Methods In this observational study, we evaluated IgG responses to NANP-repeat, C-terminus, and full-length
circumsporozoite protein constructs at five timepoints before and after primary and booster vaccination, in children
aged 5–17 months from six African countries enrolled in the RTS,S/AS01E
phase 3 trial (NCT00866619, 2009–11).
Antibody kinetics were analysed with linear regressions, and associations with clinical malaria risk over 1 year with
Cox models.
Findings Between May 25, 2009, to March 5, 2010, 1292 children were recruited and included for analysis in this study.
IgG levels declined more slowly for C-terminus than for NANP-repeat over 17 months after primary vaccination
(geometric mean fold change 0·099 [95% CI 0·089–0·110] vs 0·055 [0·048–0·062]; p<0·0001). The booster
significantly enhanced C-terminal IgG, exceeding post-primary peak levels (geometric mean fold change 1·98 [95% CI
1·77–2·21]), whereas NANP-repeat responses were restored but remained below post-primary levels (geometric mean
fold changes 0·57 [95% CI 0·51–0·63]). Higher circumsporozoite protein IgG levels correlated with reduced malaria
risk, particularly during maintenance phases, with stronger associations for C-terminus, which remained
independently protective after adjustment for NANP-repeat antibodies (hazard ratio 0·60, 95% CI 0·43–0·83;
p=0·0021). After boosting, maintenance but not peak IgG levels correlated with reduced malaria risk.
Interpretation IgG to circumsporozoite protein C-terminus are more durable than those to the NANP-repeats.
Antibody maintenance emerges as a stronger predictor of RTS,S/AS01E
vaccine efficacy than peak responses.
Description
Research Article
Citation
Lara-Escandell, M., Sánchez, L., Macià, D., Jairoce, C., Mpina, M., Sorgho, H., ... & Dobaño, C. (2026). Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS, S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial. The Lancet Infectious Diseases.
